Free public records show ADARx Pharmaceuticals, Inc. in 2 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by ADARx Pharmaceuticals, Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Source: SEC EDGAR, Company filings, CIK 1802369. Retrieved 13 Nov 2026.
9 active studies led by ADARx Pharmaceuticals, Inc., of 9 in all
Source: ClinicalTrials.gov, Studies with ADARx Pharmaceuticals, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1802369.
Studies ADARx Pharmaceuticals, Inc. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with ADARx Pharmaceuticals, Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show ADARx Pharmaceuticals, Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets ADARx Pharmaceuticals, Inc. is in.
Stories on the topics ADARx Pharmaceuticals, Inc. works in.
WHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient…
Read
Every vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches…
Read
The first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
ReadSearch all reports for ADARx Pharmaceuticals, Inc. All companies